These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28894944)

  • 1. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
    Yu L; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
    [No Abstract]   [Full Text] [Related]  

  • 4. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Zhang Q; Li Z; Hou Y; Dang H; Chen J; Liang L; Wang Q; Cao C; Zhao H; Gui R; Zu Y; Zhou J; Yu F; Wang J; Song Y; Zhang Y
    Ann Palliat Med; 2022 Apr; 11(4):1336-1350. PubMed ID: 35523742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
    Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
    [No Abstract]   [Full Text] [Related]  

  • 8. [A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients'perspective].
    Jiang Q; Liu ZC; Zhang SX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):559-64. PubMed ID: 27535854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
    Jiang Q; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
    Yu L; Wang HB; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):929-935. PubMed ID: 27995875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Yu L; Huang X; Gale RP; Wang H; Jiang Q
    Medicine (Baltimore); 2019 Nov; 98(48):e18079. PubMed ID: 31770225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].
    Liu YT; Zhang XS; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):760-765. PubMed ID: 36709170
    [No Abstract]   [Full Text] [Related]  

  • 16. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.
    Yu L; Wang H; Gale RP; Qin Y; Lai Y; Shi H; Dou X; Huang X; Jiang Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):449-459. PubMed ID: 33835260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia – a model disease for targeted therapy].
    Richter J; Stenke L
    Lakartidningen; 2017 Sep; 114():. PubMed ID: 28949401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.